Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?
Authors:
Open Access
- 3 August 2024
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 209, 114262
Abstract
No abstract availableKeywords
Funding Information
- Stichting Kwaliteitsgelden Medisch Specialisten
This publication has 43 references indexed in Scilit:
- Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectivenessEuropean Journal of Cancer, 2024
- Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesisPharmacology Research & Perspectives, 2021
- Single‐Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: A Retrospective Cohort Study of Centralized European Marketing Authorizations Between 2010 and 2019Clinical Pharmacology & Therapeutics, 2020
- Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved DrugsClinical Pharmacology & Therapeutics, 2018
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentCancer, 2015
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialThe Lancet Oncology, 2014
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety studyEuropean Journal of Cancer, 2013
- Results of a GlobaL Phase II Study with Crizotinib in Advanced ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)Annals of Oncology, 2012
- Combined weekly topotecan and biweekly bevacizumab in women with platinum‐resistant ovarian, peritoneal, or fallopian tube cancerCancer, 2011